Article

Eye-care products stolen

Novartis and its Alcon division are working with the FDA, industry cargo thefts organizations, and law enforcement officials to recover products of Novartis, Alcon, and Falcon, a line of generic eye-care pharmaceuticals from the Sandoz division of Novartis, that were stolen on July 18 while being delivered to a customer?s distribution center in Florida.

Basel, Switzerland-Novartis and its Alcon division are working with the FDA, industry cargo thefts organizations, and law enforcement officials to recover products of Novartis, Alcon, and Falcon (a line of generic eye-care pharmaceuticals from the Sandoz division of Novartis) that were stolen on July 18 while being delivered to a customer’s distribution center in Florida.

The stolen nutritional supplements, lens care solutions, and prescription and over-the-counter medications represent a small portion of each product lot, which already have been distributed within the United States, Puerto Rico, and its territories. Products delivered before July 18 were not involved in the theft.

Novartis, Alcon, and the FDA are advising physicians, retailers, and consumers to purchase products only from trusted and reliable sources and to check all products for signs of tampering or damage before purchase and/or use. Products should not be used if the packaging appears to have been disturbed.

A list of the affected products can be found here: http://invest.alconinc.com/phoenix.zhtml?c=130946&p=irol-pressReleasesArticle&ID=1596237&highlight=

Anyone who has information regarding the theft or who has received suspicious or unsolicited offers for the specified products since July 18 should contact the FDA Office of Criminal Investigations (OCI) at 800/551-3989 or visit the OCI Web site at www.fda.gov/OCI. Patient or customer inquiries should be directed to Novartis Consumer Health Customer Relations at 800/452-0051 or Alcon/Falcon Customer Service at 800/862-5266.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.